Document is current
Any future updates will be listed below
-
Authors
Sullivan, Daniel I.
Ascherman, Dana P.
-
Funding
Funding for this research was provided by:
Boehringer Ingelheim (SRA00002825. Myositis Interstitial Lung Disease Nintedanib Trial (MINT)., Identifying Novel Serologic and Proteomic Biomarkers of Rheumatoid Arthritis-Associated Interstitial Lung Disease.)
AstraZeneca United States (D5985C00006. A Randomized, Double-blind, Two-way Crossover Study to Assess the Effect of Hydrofluoroolefin (HFO) Propellant Metered Dose Inhaler (MDI) on Mucociliary Clearance Compared with Hydrofluoroalkane (HFA) Propellant MDI in Healthy Participants.)
National Heart, Lung, and Blood Institute (R01 AR080823. Rheumatoid Arthritis-associated Parenchymal Lung Disease: Clinical and Molecular Phenotypes.)
Pittsburgh Foundation (Identifying Novel Biomarkers of Disease Progression in Rheumatoid Arthritis-Associated Interstitial Lung Disease.)
- License Information
-
More Information
Article History
Accepted: 26 June 2024
First Online: 25 September 2024
Declarations
:
: Funding: D.P.A. received funding support for this work from the following sources: 1. National Heart, Lung, and Blood Institute, R01 AR080823. Rheumatoid Arthritis-associated Parenchymal Lung Disease: Clinical and Molecular Phenotypes. 2. Boehringer Ingelheim, Identifying Novel Serologic and Proteomic Biomarkers of Rheumatoid Arthritis-Associated Interstitial Lung Disease. 3. Pittsburgh Foundation, Identifying Novel Biomarkers of Disease Progression in Rheumatoid Arthritis-Associated Interstitial Lung Disease. D.I.S. received no direct research support for this work, but did receive unrelated support from: 1. Boehringer Ingelheim, SRA00002825. Myositis Interstitial Lung Disease Nintedanib Trial (MINT). 2. AstraZeneca United States, D5985C00006. A Randomized, Double-blind, Two-way Crossover Study to Assess the Effect of Hydrofluoroolefin (HFO) Propellant Metered Dose Inhaler (MDI) on Mucociliary Clearance Compared with Hydrofluoroalkane (HFA) Propellant MDI in Healthy Participants.Financial interests: D.P.A. receives research support from the Pittsburgh Foundation and Boehringer Ingelheim (investigator initiated grant). D.I.S. receives research support from Boehringer Ingelheim (investigator initiated grant) and AstraZeneca. D.I.S. owns stock in Amgen, Eli Lilly, Johnson and Johnson, and Merck.
